Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

Jorge E. Cortes, Hagop Kantarjian, James M. Foran, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, Guy Gammon, Denise Trone, Robert C. Armstrong, Joyce James, Mark Levis

Research output: Contribution to journal › Article › peer-review

253 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status'. Together they form a unique fingerprint.

Medicine & Life Sciences